Tags

Type your tag names separated by a space and hit enter

Expert opinion on the management and follow-up of uveitis patients during SARS-CoV-2 outbreak.
Expert Rev Clin Immunol. 2020 Jul 21 [Online ahead of print]ER

Abstract

INTRODUCTION

Routine medical and ophthalmic care is being drastically curtailed in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Uveitis patients require particular attention because of their theoretical risk of viral infection, in the context of therapeutic immunosuppression.

AREAS COVERED

This collaborative work proposes practical management and follow-up criteria for uveitis patients in the context of the ongoing SARS-CoV-2 pandemic.

EXPERT OPINION

Management should proceed as usual when access to health care possible in patients who do not belong to a group at high risk of severe SARS-CoV-2 infection, and in uncontrolled uveitis cases. In case of reduced access to eye clinics or high risk of SARS-CoV-2 infection, patients' management should be stratified based on their clinical presentation. In non-severe uveitis cases, the use of systemic steroids should be avoided, and local steroids preferred whenever possible. In uncontrolled situations where there is real risk of permanent visual loss, high-dose intravenous steroids and/or systemic immunosuppressants and/or biotherapies can be administered depending on the severity of eye disease. Immunosuppressive therapy should not be withheld, unless the patient develops SARS-CoV2 infection.

Authors+Show Affiliations

Department of Ophthalmology, IHU FOReSIGHT, Sorbonne University-APHP , Paris, France.Department of Ophthalmology, IHU FOReSIGHT, Sorbonne University-APHP , Paris, France.Department of Ophthalmology, Aneurin Bevan University Health Board , Newport, UK.Department of Ophthalmology, Cantonal Hospital Lucerne , Lucerne, Switzerland.Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health , Berlin, Germany.Department of Ophthalmology and Visual Sciences, University of British Columbia , Vancouver, Canada.Singapore National Eye Center , Singapore, Singapore.Department of Internal Medicine, Pitié Salpétrière University Hospital, Sorbonne University-APHP , Paris, France.Center for Advanced Vision Science, Department of Ophthalmology, Department of Pathology, Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine , Charlottesville, VA, USA.Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv, Israel.Department of Ophthalmology, IHU FOReSIGHT, Sorbonne University-APHP , Paris, France.Department of Ophthalmology, University of Leiden, the Netherlands; MIOS - Retina and Ocular Inflammation Center , Lausanne, Switzerland.Department of Ophthalmology, IHU FOReSIGHT, Sorbonne University-APHP , Paris, France.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32615046

Citation

Stanescu-Segall, Dinu, et al. "Expert Opinion On the Management and Follow-up of Uveitis Patients During SARS-CoV-2 Outbreak." Expert Review of Clinical Immunology, 2020, pp. 1-7.
Stanescu-Segall D, Sales de Gauzy T, Reynolds R, et al. Expert opinion on the management and follow-up of uveitis patients during SARS-CoV-2 outbreak. Expert Rev Clin Immunol. 2020.
Stanescu-Segall, D., Sales de Gauzy, T., Reynolds, R., Faes, L., Pohlmann, D., Pakzad-Vaezi, K., Ting, D., Saadoun, D., Ambati, J., Loewenstein, A., Bodaghi, B., de Smet, M. D., & Touhami, S. (2020). Expert opinion on the management and follow-up of uveitis patients during SARS-CoV-2 outbreak. Expert Review of Clinical Immunology, 1-7. https://doi.org/10.1080/1744666X.2020.1791086
Stanescu-Segall D, et al. Expert Opinion On the Management and Follow-up of Uveitis Patients During SARS-CoV-2 Outbreak. Expert Rev Clin Immunol. 2020 Jul 21;1-7. PubMed PMID: 32615046.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expert opinion on the management and follow-up of uveitis patients during SARS-CoV-2 outbreak. AU - Stanescu-Segall,Dinu, AU - Sales de Gauzy,Thomas, AU - Reynolds,Rhianon, AU - Faes,Livia, AU - Pohlmann,Dominika, AU - Pakzad-Vaezi,Kaivon, AU - Ting,Daniel, AU - Saadoun,David, AU - Ambati,Jayakrishna, AU - Loewenstein,Anat, AU - Bodaghi,Bahram, AU - de Smet,Marc D, AU - Touhami,Sara, Y1 - 2020/07/21/ PY - 2020/7/3/pubmed PY - 2020/7/3/medline PY - 2020/7/3/entrez KW - SARS-CoV-2 KW - Uveitis KW - biologics KW - coronavirus KW - corticosteroid KW - immunosuppression KW - immunosuppressive therapy KW - intravitreous injection KW - management SP - 1 EP - 7 JF - Expert review of clinical immunology JO - Expert Rev Clin Immunol N2 - INTRODUCTION: Routine medical and ophthalmic care is being drastically curtailed in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Uveitis patients require particular attention because of their theoretical risk of viral infection, in the context of therapeutic immunosuppression. AREAS COVERED: This collaborative work proposes practical management and follow-up criteria for uveitis patients in the context of the ongoing SARS-CoV-2 pandemic. EXPERT OPINION: Management should proceed as usual when access to health care possible in patients who do not belong to a group at high risk of severe SARS-CoV-2 infection, and in uncontrolled uveitis cases. In case of reduced access to eye clinics or high risk of SARS-CoV-2 infection, patients' management should be stratified based on their clinical presentation. In non-severe uveitis cases, the use of systemic steroids should be avoided, and local steroids preferred whenever possible. In uncontrolled situations where there is real risk of permanent visual loss, high-dose intravenous steroids and/or systemic immunosuppressants and/or biotherapies can be administered depending on the severity of eye disease. Immunosuppressive therapy should not be withheld, unless the patient develops SARS-CoV2 infection. SN - 1744-8409 UR - https://www.unboundmedicine.com/medline/citation/32615046/Expert_Opinion_on_the_Management_and_Follow-up_of_Uveitis_Patients_during_SARS-CoV-2_Outbreak L2 - http://www.tandfonline.com/doi/full/10.1080/1744666X.2020.1791086 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.